AKR1A1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population disrupting the AKR1A1 gene in the HAP1 near-haploid cell line. This population eliminates AKR1A1 enzymatic activity, abolishing NADPH-dependent aldehyde and ketone reduction. The polyclonal pool contains a heterogeneous collection of gene-disrupted alleles generated by non-homologous end joining, avoiding clonal bias and providing a robust loss-of-function model for population-level phenotypic and pharmacological analyses.
The HAP1 cell line is a near-haploid derivative of the KBM-7 chronic myeloid leukemia line, featuring a predominantly haploid karyotype and suspension growth. This genetic simplicity enables unambiguous knockout phenotyping by reducing functional redundancy, making it ideal for genetic screens, drug target validation, and pathway dissection. HAP1 cells retain key cancer and stress-response signaling networks, and the haploid genome streamlines editing and analysis.
AKR1A1 encodes a cytosolic aldo-keto reductase that uses NADPH as a cofactor to reduce toxic aldehydes and ketones, including methylglyoxal and 3-deoxyglucosone, thereby detoxifying reactive carbonyl species generated from glycolysis and lipid peroxidation. The enzyme functions downstream of the NRF2 transcription factor, which is activated by electrophilic stress and ROS via the ARE. Its primary substrates, methylglyoxal and 3-deoxyglucosone, are precursors of AGEs; reduction to lactaldehyde prevents protein glycation and maintains redox balance. Interacting factors include NADPH, aldehyde dehydrogenases, and the glyoxalase system. Knockout impairs this pathway, leading to methylglyoxal accumulation, oxidative stress, and glycation.
In the HAP1 cellular context, loss of AKR1A1 disrupts endogenous pathways responsible for carbonyl detoxification, rendering cells acutely sensitive to exogenous and endogenous RCS. This model recapitulates cellular vulnerabilities seen in diseases of carbonyl stress, such as diabetic complications, where methylglyoxal accumulation drives AGE formation and tissue damage. The near-haploid background eliminates any buffering from a second allele, enabling clear delineation of dose-dependent effects of NRF2 pathway activation and other stress-responsive transcriptional programs. Consequently, these cells serve as a stringent platform for investigating the molecular determinants of redox homeostasis and RCS pathophysiology.
Designed for advanced research, these cells support studies of aldehyde detoxification, diabetic complications, oxidative stress, drug metabolism, and NRF2 pathway biology. Applications include genetic screens for detoxification genes and protein glycation research. Typical assays are Western blotting, enzyme activity assays, methylglyoxal quantification via LC-MS, ROS measurement, cell viability under carbonyl stress, NRF2 pathway activation assays, and RNA-seq transcriptional profiling. This model offers a physiologically relevant system for dissecting carbonyl detoxification defects. For technical inquiries, contact Ascent Research.
